Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve (IROCHIM)
Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant chemotherapy for systemic lupus erythematosus (Group 1), breast cancer (Group 2) or Hodgkin disease (Group 3)to evaluate the clinical and biological markers of ovarian reserve. The follow-up will last 24 months for each patients with a visit before treatment, and at 3 months, 6 months, one year and two years after treatment.
During this period, we will collect pre and post treatment clinical data,and biological data and ultrasonographic data such as antral follicle count which is a marker of ovarian follicle reserve.These data were not observed in current practice.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Clamart, France, 92141
- AP-HP Hôpital Antoine Beclere
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women volunteers treated by chemotherapy,
- ≥ 18 and ≤ 35 years old
- Regular menstrual cyclicity, between 25 and 35 days
- Social security affiliation
- Signed informed consent
Exclusion Criteria:
- Women < 18 and > 35 years old
- Pregnancy
- Emergent treatment necessity
- No social security affiliation
- Virgin patients
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 1
systemic lupus erythematosus
|
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Other Names:
|
|
Other: 2
breast cancer
|
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Other Names:
|
|
Other: 3
Hodgkin disease
|
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AMH level and antral follicle count
Time Frame: one year after the chemotherapy treatment
|
one year after the chemotherapy treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AMH level and antral follicle count at each visit
Time Frame: 3 months, 6 months, and two years after the chemotherapy treatment
|
3 months, 6 months, and two years after the chemotherapy treatment
|
|
Hormonal status (Estradiol, LH, FSH and progesterone levels)
Time Frame: 3 months, 6 months, and two years after the chemotherapy treatment
|
3 months, 6 months, and two years after the chemotherapy treatment
|
|
Menstrual cyclicity
Time Frame: 3 months, 6 months, and two years after the chemotherapy treatment
|
3 months, 6 months, and two years after the chemotherapy treatment
|
|
pregnancy
Time Frame: 3 months, 6 months, and two years after the chemotherapy treatment
|
3 months, 6 months, and two years after the chemotherapy treatment
|
|
infertility treatment if required
Time Frame: 3 months, 6 months, and two years after the chemotherapy treatment
|
3 months, 6 months, and two years after the chemotherapy treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Renato Fanchin, MD, Assistance Publique - Hôpitaux de Paris Hôpital Antoine Béclère
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infertility
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Cyclophosphamide
- Vinblastine
Other Study ID Numbers
Other Study ID Numbers
- P070707
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.